Literature DB >> 17550372

Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma.

P Deepak1, S Kumar, A Acharya.   

Abstract

Spontaneously arising transplantable T cell lymphoma, designated as Dalton's lymphoma (DL), is characterized by a highly invasive and deleterious nature almost completely paralysing the host immune system. The level of interleukin (IL)-13 is elevated in serum and ascitic fluid of the DL-bearing host. IL-13 is a potent immunosuppressive cytokine and is an alternative activator of macrophages that suppresses the production of nitric oxide (NO) and expression of inducible nitric oxide synthase (iNOS), and proinflammatory cytokines. The expression of iNOS and proinflammatory cytokines are dependent largely upon the activation of nuclear factor-kappaB (NF-kappaB). Activation of NF-kappaB involves the degradation of cytoplasmic inhibitor IkappaBalpha, allowing the nuclear translocation of NF-kappaB and thereby transcription of the iNOS gene. Therefore, in this study we sought to determine whether the alternative activation or type II polarization of macrophages induced by IL-13 is mediated by the suppression of NF-kappaB and cytoplasmic preservation of IkappaBalpha. Western blot analysis and electrophoretic mobility shift assay (EMSA) indicate that tumour-associated macrophages (TAM) or polarized type II macrophages are due to preserved protein expression of IkappaBalpha, and therefore suppressed NF-kappaB nuclear translocation. These findings suggest that IL-13 may operate through the suppression of NF-kappaB activation and preservation of IkappaBalpha.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17550372      PMCID: PMC1941949          DOI: 10.1111/j.1365-2249.2007.03427.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

Review 1.  The many faces of macrophage activation.

Authors:  David M Mosser
Journal:  J Leukoc Biol       Date:  2003-02       Impact factor: 4.962

Review 2.  The NF-kappa B and I kappa B proteins: new discoveries and insights.

Authors:  A S Baldwin
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Stat3 activation by Src induces specific gene regulation and is required for cell transformation.

Authors:  J Turkson; T Bowman; R Garcia; E Caldenhoven; R P De Groot; R Jove
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population.

Authors:  C Bogdan; H Thüring; M Dlaska; M Röllinghoff; G Weiss
Journal:  J Immunol       Date:  1997-11-01       Impact factor: 5.422

Review 5.  NF-kappaB activation: the I kappaB kinase revealed?

Authors:  I Stancovski; D Baltimore
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

Review 6.  Transcription factor NF-kappaB: a sensor for smoke and stress signals.

Authors:  Kwang Seok Ahn; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

7.  Gender dimorphism in the progressive in vivo growth of a T cell lymphoma: involvement of cytokines and gonadal hormones.

Authors:  Mahendra Pal Singh; Ambak Kumar Rai; Sukh Mahendra Singh
Journal:  J Reprod Immunol       Date:  2005-02       Impact factor: 4.054

8.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function.

Authors:  A N McKenzie; J A Culpepper; R de Waal Malefyt; F Brière; J Punnonen; G Aversa; A Sato; W Dang; B G Cocks; S Menon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B.

Authors:  T Henkel; T Machleidt; I Alkalay; M Krönke; Y Ben-Neriah; P A Baeuerle
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

10.  Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10.

Authors:  R de Waal Malefyt; C G Figdor; R Huijbens; S Mohan-Peterson; B Bennett; J Culpepper; W Dang; G Zurawski; J E de Vries
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

View more
  7 in total

1.  Retraction statement.

Authors: 
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

2.  Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.

Authors:  Adam T Waickman; Angela Alme; Liana Senaldi; Paul E Zarek; Maureen Horton; Jonathan D Powell
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

3.  Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors.

Authors:  Lisa Macedo; Grace Pinhal-Enfield; Vera Alshits; Genie Elson; Bruce Neil Cronstein; Samuel Joseph Leibovich
Journal:  Am J Pathol       Date:  2007-11-01       Impact factor: 4.307

4.  Apoptosis and cytokines in non-alcoholic steatohepatitis.

Authors:  Wing-Kin Syn; Steve S Choi; Anna Mae Diehl
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

5.  Anticancer Activity of Garcinia morella on T-Cell Murine Lymphoma Via Apoptotic Induction.

Authors:  Bhaswati Choudhury; Raghuram Kandimalla; Rupjyoti Bharali; Javadi Monisha; Ajaikumar B Kunnumakara; Kasturi Kalita; Jibon Kotoky
Journal:  Front Pharmacol       Date:  2016-01-29       Impact factor: 5.810

6.  Interleukin-13 inhibits cytokines synthesis by blocking nuclear factor-κB and c-Jun N-terminal kinase in human mesangial cells.

Authors:  Chunhua Zhu; Aihua Zhang; Songming Huang; Guixia Ding; Xiaoqin Pan; Ronghua Chen
Journal:  J Biomed Res       Date:  2010-07

7.  Increased Th1 Cells with Disease Resolution of Active Pulmonary Tuberculosis in Non-Atopic Patients.

Authors:  Chun-Yu Lo; Yu-Chen Huang; Hung-Yu Huang; Fu-Tsai Chung; Chang-Wei Lin; Kian Fan Chung; Chun-Hua Wang
Journal:  Biomedicines       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.